Compare JPMorgan Equity Premium Income ETF (JEPI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

JPMorgan Equity Premium Income ETFTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

JPMorgan Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.64, while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

	JEPI	VRTX
Sector	Income / Options Overlay	Health
52-Week High	$59.88	$529.59
52-Week Low	$55.29	$366.54
Market Cap	—	$121.95B
Enterprise Value	—	$116.69B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JEPI

RYLD ETF's covered call strategy limits small-cap gains compared to direct Russell 2000 ETFs.24/7 Wall Street · 3 days agoBearish JPMorgan Equity Premium ETF underperforms S&P 500 and peers due to sector weight and strategy issues.Seeking Alpha · 4 days agoBearish View details →

VRTX

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 15 hours agoNeutral View details →

About JPMorgan Equity Premium Income ETF

JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.